The Discounted Cash Flow (DCF) valuation of Biomarin Pharmaceutical Inc (BMRN) is 84.00 USD. With the latest stock price at 58.82 USD, the upside of Biomarin Pharmaceutical Inc based on DCF is 42.8%.
Based on the latest price of 58.82 USD and our DCF valuation, Biomarin Pharmaceutical Inc (BMRN) is a buy. buying Biomarin stocks now will result in a potential gain of 42.8%.
| Range | Selected | |
| WACC / Discount Rate | 6.1% - 8.1% | 7.1% |
| Long-term Growth Rate | 3.0% - 5.0% | 4.0% |
| Fair Price | 53.57 - 222.20 | 84.00 |
| Upside | -8.9% - 277.8% | 42.8% |